Terminated PHASE2 INTERVENTIONAL 2-arm NCT00825227

Safety and Efficacy of Armodafinil for Fatigue Associated With Taxanes Alone or in Combination With Other Agents

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Armodafinil Treatment (150 mg/Day) for Patients With Fatigue Associated With Taxane Chemotherapy Alone or in Combination With Other Agents

Sponsor: Cephalon

Conditions Chemotherapy Side Effects Fatigue

Interventions Armodafinil 150 mg/day Placebo,

Updated 12 times since 2017 Last updated: Oct 12, 2017 Started: Dec 31, 2008 Primary completion: Oct 31, 2009 Completion: Feb 28, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Cephalon

See all terminations from Cephalon

Listed as NCT00825227, this PHASE2 trial focuses on Chemotherapy Side Effects and Fatigue and remains terminated or withdrawn. Sponsored by Cephalon, it has been updated 12 times since 2008, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2

▶ Show 7 earlier versions

Jan 2022 — Dec 2022 [monthly]

Terminated PHASE2
Dec 2021 — Jan 2022 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Dec 2017 — Jun 2018 [monthly]

Terminated PHASE2
Feb 2017 — Dec 2017 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cephalon

Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abingdon, United States , Atlanta, United States , Augusta, United States , Bethesda, United States , Billings, United States , Burbank, United States , Cedar Rapids, United States , Charleston, United States , Danville, United States , Fountain Valley, United States and 18 more locations